1. |
中国女医师协会临床肿瘤学专业委员会, 中国抗癌协会乳腺癌专业委员会.中国进展期乳腺癌共识指南(CABC 2015).癌症进展, 2015, 13(3):223-245.
|
2. |
刘荫华, 刘倩.客观解读RECIST(修订版)的临床评价意义.中国实用外科杂志, 2010, 30(1):31-33.
|
3. |
文芳, 翁洁, 罗盘.吉西他滨联合卡培他滨二线治疗晚期乳腺癌的疗效评价.中国肿瘤外科杂志, 2015, 7(3):184-185, 188.
|
4. |
郑莹, 吴春晓, 张敏璐.乳腺癌在中国的流行状况和疾病特征.中国癌症杂志, 2013, 23(8):561-569.
|
5. |
Borson R, Harker G, Reeves J, et al. Phase Ⅱ study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer. Clin Breast Cancer, 2012, 12(5):322-330.
|
6. |
Mangini NS, Wesolowski R, Ramaswamy B, et al. Palbociclib:a novel cyclin-dependent kinase inhibitor for hormone receptor-positive advanced breast cancer. Ann Pharmacother, 2015, 49(11):1252-1260.
|
7. |
Lawson DA, Bhakta NR, Kessenbrock K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature, 2015, 526(7571):131-135.
|
8. |
Golubnitschaja O, Yeghiazaryan K, Costigliola V, et al. Risk assessment, disease prevention and personalised treatments in breast cancer:is clinically qualified integrative approach in the horizon. EPMA J, 2013, 4(1):6.
|
9. |
徐兵河.晚期乳腺癌的治疗原则与策略.中国医药导报, 2010, 7(6):6-8.
|
10. |
张志强, 江泽飞, 宋三泰.吉西他滨在乳腺癌化疗中的临床应用.国外医学:肿瘤学分册, 2003, 30(2):132-135.
|
11. |
中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版).中国癌症杂志, 2015, 25(9):692-754.
|
12. |
Seidman AD, Chan S, Wang J, et al. A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. Oncologist, 2014, 19(5):443-452.
|
13. |
Garcia AA, Yessaian A, Pham H, et al. PhaseⅡ study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer. Cancer Invest, 2012, 30(4):295-299.
|
14. |
张丹华, 周恩相.紫杉醇注射液、紫杉醇脂质体以及多西他赛治疗乳腺癌的疗效及安全性.中国癌症杂志, 2013, 23(12):1014-1016.
|
15. |
Ghersi D, Willson ML, Chan MM, et al. Taxane-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev, 2015, (6):CD003366.
|
16. |
马焱, 孟祥颖, 吴世凯, 等.多西他赛解救治疗紫杉醇耐药的转移性乳腺癌的临床研究.癌症进展, 2012, 10(3):251-256.
|
17. |
向其德, 覃事鹏, 谭力, 等.吉西他滨联合多西他赛治疗蒽环类耐药性晚期乳腺癌的临床观察.现代医药卫生, 2013, 29(20):3067-3068.
|
18. |
Ciruelos EM, Cortés J, Cortés-Funes H, et al. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer:a multicenter phaseⅡ study (SOLTI 0301 trial). Ann Oncol, 2010, 21(7):1442-1447.
|
19. |
Karachaliou N, Ziras N, Syrigos K, et al. A multicenter phaseⅡ trial of docetaxel and capecitabine as salvage treatment in anthracyclineand taxane-pretreated patients with metastatic breast cancer. Cancer Chemother Pharmacol, 2012, 70(1):169-176.
|
20. |
张慎锋, 田涛, 王文朋, 等.多西他赛联合吉西他滨治疗复发转移性乳腺癌临床疗效及预后影响因素.国际肿瘤学杂志, 2013, 40(8):634-638.
|
21. |
谢剑明, 谢亚琳, 刘斐烨, 等.多西他赛联合吉西他滨治疗转移性乳腺癌效果观察.中国热带医学, 2010, 10(10):1265-1266.
|
22. |
Yi SY, Ahn JS, Uhm JE, et al. Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype. BMC Cancer, 2010, 10(1):527-534.
|
23. |
Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol, 2009, 20(12):1953-1958.
|
24. |
Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol, 2012, 30(6):587-592.
|
25. |
骆梅青, 李锡清.不同分子亚型的晚期乳腺癌化疗疗效观察.现代肿瘤医学, 2010, 18(5):914-917.
|